Katherine A. Stueland's most recent trade in GeneDx Holdings Corp - Ordinary Shares - Class A was a trade of 80,000 Restricted Stock Unit done . Disclosure was reported to the exchange on March 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2026 | 80,000 | 160,000 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2026 | 80,000 | 138,447 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 63.28 per share. | 26 Mar 2026 | 13,412 | 106,689 | - | 63.3 | 848,699 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 61.29 per share. | 26 Mar 2026 | 13,229 | 125,218 | - | 61.3 | 810,817 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 65.21 per share. | 26 Mar 2026 | 9,883 | 91,514 | - | 65.2 | 644,513 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 64.60 per share. | 26 Mar 2026 | 5,292 | 101,397 | - | 64.6 | 341,859 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 62.33 per share. | 26 Mar 2026 | 5,117 | 120,101 | - | 62.3 | 318,952 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 18,750 | 75,626 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 18,750 | 75,000 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 11,921 | 56,876 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 11,921 | 35,763 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 77.05 per share. | 15 Mar 2026 | 9,229 | 59,219 | - | 77.0 | 711,090 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 76.35 per share. | 15 Mar 2026 | 7,178 | 68,448 | - | 76.3 | 548,035 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 77.94 per share. | 15 Mar 2026 | 772 | 58,447 | - | 77.9 | 60,166 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 6,546 | 19,640 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 6,546 | 48,633 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 86.75 per share. | 09 Mar 2026 | 3,678 | 44,955 | - | 86.7 | 319,059 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 88.11 per share. | 06 Mar 2026 | 3,404 | 42,087 | - | 88.1 | 299,926 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 3,874 | 18,111 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 3,874 | 3,874 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 94.00 per share. | 29 Jan 2026 | 1,653 | 16,458 | - | 94.0 | 155,375 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2025 | 18,750 | 25,094 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2025 | 18,750 | 93,750 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 141.20 per share. | 16 Dec 2025 | 2,679 | 21,015 | - | 141.2 | 378,287 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 146.93 per share. | 16 Dec 2025 | 1,970 | 15,873 | - | 146.9 | 289,449 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 145.36 per share. | 16 Dec 2025 | 1,628 | 17,843 | - | 145.4 | 236,640 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 140.08 per share. | 16 Dec 2025 | 1,031 | 23,694 | - | 140.1 | 144,425 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 144.27 per share. | 16 Dec 2025 | 940 | 19,471 | - | 144.3 | 135,617 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 148.55 per share. | 16 Dec 2025 | 932 | 14,941 | - | 148.5 | 138,448 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 142.12 per share. | 16 Dec 2025 | 604 | 20,411 | - | 142.1 | 85,840 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 138.93 per share. | 16 Dec 2025 | 369 | 24,725 | - | 138.9 | 51,265 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 140.95 per share. | 16 Dec 2025 | 356 | 14,237 | - | 140.9 | 50,178 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 149.20 per share. | 16 Dec 2025 | 274 | 14,667 | - | 149.2 | 40,880 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 150.76 per share. | 16 Dec 2025 | 74 | 14,593 | - | 150.8 | 11,156 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 6,547 | 9,983 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 6,547 | 26,186 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 159.28 per share. | 09 Dec 2025 | 3,639 | 6,344 | - | 159.3 | 579,620 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2025 | 3,874 | 7,748 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2025 | 3,874 | 5,594 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 136.54 per share. | 29 Oct 2025 | 2,154 | 3,440 | - | 136.5 | 294,107 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 136.75 per share. | 29 Oct 2025 | 4 | 3,436 | - | 136.8 | 547 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 108.55 per share. | 30 Sep 2025 | 5,163 | 3,255 | - | 108.6 | 560,457 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 107.61 per share. | 30 Sep 2025 | 4,462 | 8,418 | - | 107.6 | 480,160 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 106.69 per share. | 30 Sep 2025 | 1,092 | 12,880 | - | 106.7 | 116,506 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 111.84 per share. | 30 Sep 2025 | 645 | 1,856 | - | 111.8 | 72,134 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 105.10 per share. | 30 Sep 2025 | 606 | 13,972 | - | 105.1 | 63,690 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 109.13 per share. | 30 Sep 2025 | 554 | 2,701 | - | 109.1 | 60,458 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 110.23 per share. | 30 Sep 2025 | 200 | 2,501 | - | 110.2 | 22,046 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 113.68 per share. | 30 Sep 2025 | 136 | 1,720 | - | 113.7 | 15,460 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2025 | 18,750 | 112,500 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2025 | 18,750 | 25,079 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 121.47 per share. | 16 Sep 2025 | 10,501 | 14,578 | - | 121.5 | 1,275,585 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2025 | 6,546 | 9,986 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2025 | 6,546 | 32,733 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 128.05 per share. | 09 Sep 2025 | 3,639 | 6,347 | - | 128.1 | 465,974 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 129.06 per share. | 09 Sep 2025 | 18 | 6,329 | - | 129.1 | 2,323 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2025 | 3,874 | 5,594 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2025 | 3,874 | 11,622 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 105.31 per share. | 29 Jul 2025 | 2,154 | 3,440 | - | 105.3 | 226,838 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 93.00 per share. | 09 Jul 2025 | 3,220 | 1,720 | - | 93 | 299,460 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 90.68 per share. | 01 Jul 2025 | 6,928 | 7,669 | - | 90.7 | 628,215 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Stueland Katherine A. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 91.55 per share. | 01 Jul 2025 | 2,594 | 5,075 | - | 91.6 | 237,483 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Stueland A. Katherine | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 92.46 per share. | 01 Jul 2025 | 135 | 4,940 | - | 92.5 | 12,482 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 18,750 | 131,250 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 18,750 | 25,098 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 64.77 per share. | 16 Jun 2025 | 10,501 | 14,597 | - | 64.8 | 680,181 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 6,547 | 9,987 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 6,547 | 39,279 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.55 per share. | 09 Jun 2025 | 3,639 | 6,348 | - | 72.5 | 264,009 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 3,874 | 5,594 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 3,874 | 15,496 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 113.09 per share. | 29 Apr 2025 | 2,154 | 3,440 | - | 113.1 | 243,596 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 93.33 per share. | 09 Apr 2025 | 9,628 | 13,283 | - | 93.3 | 898,558 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 86.34 per share. | 09 Apr 2025 | 5,855 | 28,084 | - | 86.3 | 505,549 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 94.55 per share. | 09 Apr 2025 | 4,511 | 8,772 | - | 94.6 | 426,517 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.25 per share. | 09 Apr 2025 | 3,297 | 39,859 | - | 83.3 | 274,486 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 85.44 per share. | 09 Apr 2025 | 3,175 | 33,939 | - | 85.4 | 271,262 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 96.29 per share. | 09 Apr 2025 | 3,174 | 2,425 | - | 96.3 | 305,637 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 95.51 per share. | 09 Apr 2025 | 3,173 | 5,599 | - | 95.5 | 303,053 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.17 per share. | 09 Apr 2025 | 3,134 | 43,156 | - | 82.2 | 257,509 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 84.28 per share. | 09 Apr 2025 | 2,745 | 37,114 | - | 84.3 | 231,348 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 81.16 per share. | 09 Apr 2025 | 2,024 | 46,290 | - | 81.2 | 164,262 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 91.27 per share. | 09 Apr 2025 | 1,900 | 23,911 | - | 91.3 | 173,420 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 90.13 per share. | 09 Apr 2025 | 1,600 | 25,811 | - | 90.1 | 144,207 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 92.28 per share. | 09 Apr 2025 | 1,000 | 22,911 | - | 92.3 | 92,280 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 97.24 per share. | 09 Apr 2025 | 705 | 1,720 | - | 97.2 | 68,557 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 87.30 per share. | 09 Apr 2025 | 373 | 27,711 | - | 87.3 | 32,563 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 88.70 per share. | 09 Apr 2025 | 300 | 27,411 | - | 88.7 | 26,609 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 80,000 | 94,865 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 80,000 | 240,000 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 95.66 per share. | 26 Mar 2025 | 44,801 | 50,064 | - | 95.7 | 4,285,561 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 94.59 per share. | 26 Mar 2025 | 1,750 | 48,314 | - | 94.6 | 165,524 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2025 | 6,546 | 45,826 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2025 | 6,546 | 10,483 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 94.73 per share. | 09 Mar 2025 | 2,731 | 7,752 | - | 94.7 | 258,695 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 3,874 | 19,370 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 3,874 | 5,594 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.48 per share. | 29 Jan 2025 | 1,657 | 3,937 | - | 78.5 | 130,046 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 93.34 per share. | 07 Jan 2025 | 23,800 | 29,340 | - | 93.3 | 2,221,442 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 96.39 per share. | 07 Jan 2025 | 10,005 | 1,720 | - | 96.4 | 964,359 | Class A Common Stock |
| GeneDx Holdings Corp (Class A) | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 95.50 per share. | 07 Jan 2025 | 9,176 | 11,725 | - | 95.5 | 876,282 | Class A Common Stock |